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The serine/threonine kinase PIM1, cooperates with MYC in cell cycle progression and 
tumorigenesis. However, the nature of this cooperation remains elusive. Here we show 
that following growth factor stimulation,  PIM1 forms a complex with the MYC/MAX 
dimer via the MYC BoxII domain (MBII). MYC recruits PIM1 to the E boxes of the 
MYC-target genes FOSL1 (FRA1) and ID2 and PIM1 phosphorylates Serine 10 of 
histone H3 (H3S10) on the nucleosome at the MYC-binding sites contributing to their 
transcriptional activation.  MYC and PIM1 co-localize at sites of active transcription 
and expression profile analysis revealed that PIM1 contributes to the regulation of 
20% of the MYC-regulated genes. Moreover, PIM1-dependent H3S10 
phosphorylation contributes to MYC transforming capacity. These results establish a 
new function for PIM1 as a MYC cofactor that phosphorylates the chromatin at 
MYC-target loci and suggest that nucleosome phosphorylation, at E boxes, 
contributes to MYC-dependent transcriptional activation and cellular 
transformation.
Chromatin structure plays a crucial role in eukaryotic gene transcription. Several 
transcription activators have been shown to recruit chromatin-modifying activities, which 
either mediate histone covalent modifications or ATP-dependent nucleosome mobilization. 
Covalent histone modifications including acetylation, methylation, phosphorylation and 
ubiquitinylation have been associated with gene regulation1,2. Phosphorylation of H3S10 
has been connected with transcriptional activation in different organisms and with 
chromosome condensation during mitosis3,4. In mammalian cells, growth factor 
stimulation induces rapid phosphorylation of histone H3 at Serine 10 (H3S10) at c-Jun and 
c-Fos promoters mediated by MSK1, MSK2, and RSK2 kinases4-7. In response to 
inflammatory cytokines, IKK-  !phosphorylates H3S10 at NF-kB-responsive 
promoters8,9. 
In this study, we analyzed the function of PIM1, a constitutively active serine/threonine 
kinase. Pim1 was first identified as a common insertion site in T cell lymphomas induced 
by Molony murine leukemia virus (Mo-MuLV)10. RNA interference (RNAi) experiments 
demonstrated that human Pim1 (hereinafter referred to as PIM1) is essential for cell cycle 
progression of human umbilical vein endothelial cells (HUVEC) and for differentiation of 
endothelial precursors in vitro11. Myc and Pim1 have been shown to co-operate in cell 
growth and transformation. Pim1 over-expression in transgenic mice demonstrated its 
cooperation with c-Myc in cell transformation12-15 and microarray expression profiling 
showed that Pim1 is over-expressed in Myc-driven prostate tumours16. However, the 
nature of c-Myc and Pim1 cooperation in cell transformation remains elusive. 
Human c-Myc (hereinafter referred as MYC) codes for a basic helix-loop-helix leucine 
zipper (B-HLH) transcription factor that binds to the E box (CACGTG) when dimerized 
with MAX and regulates the transcription of distinct genes involved in cell cycle 
progression, apoptosis, cell growth, and differentiation17-23. The DNA binding domain of 
MYC is at the C-terminus while the N-terminal domain through the MYC boxII (MBII), 
essential for MYC-dependent cell transformation, has been shown to recruit multiprotein 
enzymatic complexes to the MYC-activated genes 24. 
To understand the function of PIM1, we investigated the molecular connection between 
PIM1 and MYC. We propose that the recruitment of PIM1 to the chromatin by MYC 
contributes to transcriptional activation of MYC-target genes by phosphorylating H3S10 at 
the E box element and suggest that this cooperation is relevant for MYC-dependent tumour 
formation. 
RESULTS
PIM1 phosphorylates the nucleosome at H3S10. 
PIM1 mRNA is induced with fast kinetics in HUVEC treated with VEGF-A11. Upon 
VEGF-A treatment PIM1 is induced and localizes in HUVEC nuclei within 40 minutes (see 
Supplementary Information Fig. S1). As PIM1 is a serine/threonine kinase with putative 
consensus sites present on histones, its nuclear localization could account for the increase 
of H3 phosphorylation observed in these cells between 60 and 90 minutes after VEGF-A 
treatment (see Supplementary Information Fig. S1).  We found that PIM1 could directly 
phosphorylate nucleosomes in vitro by incubating the recombinant GST-PIM1 protein with 
chromatin fractions obtained from 293 cells in the presence of  [  32P] ATP. This 
analysis revealed that a single protein, with molecular weight corresponding to H3, was 
phosphorylated by wild type GST-PIM1, but not by the kinase inactive mutant GST-PIM1-
K67M (Fig. 1a, lanes 1-3). Specific inhibition of nucleosome phosphorylation was 
observed in the presence of a peptide derived from the H3 N-terminus but not with a 
peptide derived from H2B N-terminus or with an unrelated peptide (Fig. 1a, lanes 4-12). 
PIM1 could phosphorylate reconstituted nucleosomes containing either recombinant wild 
type H3 or H3S28A, but not nucleosomes assembled with the H3S10A mutant or the 
double mutant (Fig. 1b) demonstrating that PIM1 phosphorylates H3 at S10. Histone H3 
co-immunoprecipitated with transiently expressed PIM1 or the kinase inactive mutant 
suggesting that PIM1 associates in vivo with the nucleosome (Fig. 1c). Incubation of the 
immunoprecipitate in the presence of [  32P] ATP showed that the wild type PIM1, but 
not the kinase inactive mutant PIM1-K67M phosphorylated H3. We conclude that PIM1 
associates in vitro and in vivo with H3 and directly phosphorylates H3S10 on the 
nucleosome.
PIM1 forms a complex with MYC and MAX. 
VEGF-A treatment induces MYC and PIM1 co-localization in the cell nuclei at 60 minutes, 
decreasing thereafter (Fig. 2a). We tested whether PIM1 coimmunoprecipitaes with MYC. 
Time course analysis in HUVEC treated with VEGF-A showed that upon induction, both 
MYC and PIM1 were induced with fast kinetics. Immunoprecipitations with anti-MAX 
antibodies at various time points showed the formation of the MAX/MYC complex from 
60 minutes after growth factor stimulation thus corresponding to the appearance of MYC in 
the nucleus (Fig. 2b, right panel). Importantly, PIM1 co-immunoprecipitated with MYC 
and MAX suggesting that a complex containing PIM1 is formed. Endogenous PIM1 was 
also found to co-immunoprecipitate with endogenous MYC and MAX  from 293 cells after 
serum treatment for 120 minutes (Fig. 2c), thus demonstrating that a MAX/MYC/PIM1 
endogenous complex is also formed in these cells. 
As MYC-dependent cell transformation requires MYC boxII (MBII) domain to bind 
cofactors either in a TRRAP-dependent or -independent manner24, we tested whether 
PIM1 interacts with MYC at MBII via TRRAP. Wild type FLAG-MYC or MYC deleted in 
the MBII domain (FLAG-MYC MBII) were co-expressed with PIM1 in 293 cells and 
immunoprecipitated either with FLAG or PIM1 antibodies. Western blot analysis showed 
reciprocal immunoprecipitation of FLAG-MYC with PIM1, while co-immunoprecipitation 
was strongly reduced between FLAG-MYC MBII and PIM1 suggesting that MBII 
domain of MYC is required for the formation of a complex with PIM1 (Fig. 2d). 
Endogenous TRRAP associated with MYC but not with the FLAG-MYC MBII as 
previously described 25. In contrast, PIM1 did not co-immunoprecipitate the endogenous 
TRRAP (lanes 5 and 10) suggesting that MYC forms independent complexes with PIM1 or 
TRRAP via the MBII domain. 
PIM1 co-localizes with MYC on the chromatin at actively transcribing loci. 
To measure PIM1 and MYC association at MYC-target genes, we performed a nuclear 
distribution analysis of PIM1 with respect to MYC, nascent transcripts, and chromatin 
markers. Quantitative analysis of double staining with anti-PIM1 and antibodies against 
different nuclear markers by sequential laser scanning (Fig. 3) showed an elevated degree 
of PIM1 co-localization with MYC with a Pearson’s correlation coefficient (Rr) of 
0.82±0.06. PIM1 also showed an elevated overlap with H3S10ph (Rr 0.85±0.07) and 
H3S10phK14ac while little co-localization could be detected between PIM1 and H3K9me2 
(Rr 0.37±0.03), a marker of silent heterochromatin. Furthermore, we analyzed the nuclear 
distribution of PIM1 with respect to active transcription sites by in situ transcriptional run-
on experiments. Double labelling revealed a high degree of overlap between PIM1 and 
sites of active transcription (Rr  0.77±0.05) with a pattern resembling that of transcription 
factories26. A similar pattern of nuclear localization with respect to nascent transcripts was 
observed for MYC (Rr  0.81±0.09). Taken together these results suggest that following 
growth factor treatment PIM1 kinase is mostly localized with the transcription factor MYC 
at actively transcribing sites and with phosphorylated histones.
H3S10 phosphorylation at the FOSL1 enhancer correlates with PIM1 association.
Next we analysed PIM1 association and H3S10 phosphorylation at FOSL1 (also known as 
FRA1), a well characterized MYC-target gene27,28. FOSL1 contains an upstream 
functional SRE, which is not sufficient to confer promoter activation, but requires the 
activity of a downstream enhancer that is activated by MYC and AP-127-29. Upon VEGF-
A treatment of HUVEC FOSL1 expression is induced with a peak at 60 minutes (Fig. 4a). 
To demonstrate a direct binding of MYC and PIM1 to the FOSL1 regulatory sequences 
ChIP followed by real-time quantitative PCR analysis was performed at various timepoints 
after VEGF-A treatment. As shown in Figure 4b, we generated primers to analyze four 
FOSL1 regions: a FOSL1 upstream region containing a functional SRE and a non 
canonical E box element30,31 (probe A), the downstream enhancer containing a canonical 
E box (probe B), a downstream region within the first intron (probe C), and a FOSL1 
region within the second intron (probe D). Quantitative ChIP analysis with probe B 
revealed the transient recruitment to the FOSL1 enhancer of MYC and PIM1 from 60 
minutes concomitant with a marked increase of H3S10ph signal (Fig. 4c). ChIP with probe 
B also showed a significant increase of H3S10phK9ac and H3S10phK14ac while 
H3K9acK14ac showed elevated levels before induction suggesting that, at the FOSL1 
enhancer, H3 acetylation precedes MYC binding and H3S10 phosphorylation takes place at 
the acetylated H3. 
Analysis of the upstream element (probe A) revealed MYC association with this DNA 
fragment. PIM1 did not associate with this element suggesting that the FOSL1 promoter is 
bound by an alternative MYC complex. This FOSL1 upstream element showed an increase 
of H3S10 phosphorylation at 15 minutes after VEGF-A treatment, which was therefore not 
dependent on PIM1. As the FOSL1 SRE element is constitutively occupied by the ternary 
complex factor (TCF), which is activated by the RAS/ERK pathway30, we further 
analyzed FOSL1 transcription and H3S10 phosphorylation in the presence of H89, a 
specific MSK1/MSK2 inhibitor5. Cell treatment with H89 affected FOSL1 transcription 
although a VEGF-A-dependent induction was still observed (Fig. 4d). The analysis of 
H3S10ph signal showed specific inhibition of H3S10 phosphorylation at the FOSL1 
upstream element but not at the enhancer (Fig. 4e) demonstrating that phosphorylation at 
the upstream element and at the downstream enhancer are independent from each other and 
mediated by different kinases. The acetylation pattern at the FOSL1 upstream element 
showed a significant increase of H3 phosphorylation and acetylation with a peak between 
15 and 30 minutes suggesting that, at this site, H3S10 phosphorylation precedes or is 
concomitant with H3 acetylation at K9 and K14 as previously described for IE 
promoters3,4.  
The downstream FOSL1 fragments (analyzed with probes C and D) did not reveal MYC or 
PIM1 binding, nor the increase of phosphorylated H3S10, while presented elevated levels 
of acetylated H3. These results demonstrate specific recruitment of PIM1 to the FOSL1 
enhancer concomitant with an increase of H3S10 phosphorylation at this site and with 
transcriptional activation of the gene.   
H3S10 phosphorylation at FOSL1 enhancer is mediated by PIM1.
PIM1 depletion using small hairpin RNA (shRNA) was peformed to test whether PIM1 
association with the FOSL1 enhancer was required for H3S10 phosporylation. In 293 cells 
treated with serum MYC, PIM1, and FOSL1 showed a slower kinetics of induction with 
respect to HUVEC treated with VEGF-A possibly due to the different cell types (cell line 
versus primary cells). PIM1 silencing strongly inhibited FOSL1 mRNA expression (Fig. 7b 
and see Supplementary Information Fig. S3). Quantitative ChIP analysis (Fig. 5b and see 
Supplementary Information Fig. S2) demonstrated a peak of H3S10 phosphorylation at the 
FOSL1 enhancer (probe B as described in Fig. 4b) at 120 minutes that was significantly 
reduced by PIM1 silencing, while ChIP analysis at the FOSL1 upstream element (probe A) 
showed a faster kinetics of H3S10 phosphorylation that was not affected by PIM1 
knockdown. No H3S10 phosphorylation was observed at the downstream fragments 
(probes C and D). We concluded that H3S10 phosphorylation at the FOSL1 enhancer is 
PIM1-dependent. 
PIM1 and MYC are found to associate at the FOSL1 enhancer with a peak between 90 and 
120 minutes. PIM1 silencing significantly reduced PIM1 association at the enhancer 
without affecting MYC association. The overall pattern of H3 phospho-acetylation at K9 
and K14 in 293 cells showed elevated levels of H3 acetylation already present before H3 
phosphorylation at the FOSL1 enhancer (probe B) and along the FOSL1 gene (probe C and 
D) which was not affected by PIM1 silencing. 
Moreover, expressing the kinase inactive mutant PIM1-K67M, significantly reduced 
H3S10ph levels at the FOSL1 enhancer (see Supplementary Information Fig. S3) 
demonstrating that the kinase activity of PIM1 is required for H3S10 phosphorylation at 
this site. 
PIM1 is recruited by MYC at the FOSL1 and ID2 E box elements.
MYC silencing was performed to analyze whether its expression is required for PIM1 
recruitment to the FOSL1 enhancer (Fig. 6a and see Supplementary Information Fig. S4). 
We also analyzed MYC-dependent recruitment of PIM1 at the ID2 E box. ID2 is a well 
characterized MYC-regulated gene that, differently from FOSL1, contains its functional 
MYC-binding sites upstream the promoter28,32. As expected, ChIP analysis on control 
cells showed MYC association at the FOSL1 enhancer and the ID2 E box at 120 minutes 
after serum treatment, while MYC silencing significantly reduced MYC association at 
these sites (Fig. 6b and see Supplementary Information Fig. S4). ChIP analysis revealed 
PIM1 association with both genes in control cells while MYC knockdown significantly 
reduced PIM1 association at these E boxes (Fig. 6c and see Supplementary Information 
Fig. S4). Moreover, H3S10 phosphorylation showed significant reduction in MYC silenced 
cells at these sites (Fig. 6d and see Supplementary Information Fig. S4). In contrast, 
H3K9acK14ac was unaffected by MYC silencing (Fig. 6e and see Supplementary 
Information Fig. S4) confirming that H3 acetylation is not dependent on MYC binding. 
Importantly, the reintroduction of wild type FLAG-MYC, but not the FLAG-MYC MBII 
in MYC-silenced cells restored PIM1 recruitment and H3S10 phosphorylation at both sites 
(Fig. 6 f, g, h and see Supplemenrary Information Fig. S4). These results establish that 
MYC, via its MBII domain, recruits PIM1 to the E box elements of these MYC-regulated 
genes and its recruitment is required for phosphorylating H3S10 at these sites. 
PIM1 is required for transcriptional activation of FOSL1 and ID2 genes.
After serum treatment of 293 cells, both FOSL1 and ID2 mRNA were induced with similar 
kinetics (Fig. 7b, e) corresponding to the peak of PIM1 and MYC association and H3S10 
phosphorylation in these cells. The same results were obtained by measuring FOSL1 and 
ID2 unprocessed heterogeneous nuclear RNA (hnRNA) indicating that increased mRNA 
level depend on transcriptional activation. PIM1 silencing, as well as the expression of 
PIM1-K67M, inhibited induction of both FOSL1 and ID2 transcripts (Fig 7b, e and see 
Supplementary Information Fig. S3) demonstrating that PIM1 kinase activity is required 
for full transcriptional activation of both genes.  
Quantitative ChIP analysis of RNA Polymerase II (Pol II) and as well as Pol II 
phosphorylated in Ser2 (Ser2P) at the C-terminal domain (CTD) of control cells revealed a 
significant increase in signal at FOSL1 and ID2 promoters and along the genes in response 
to serum treatment (Fig. 7c, f and see Supplementary Information Fig. S3) mirroring of the 
increase in transcript levels. PIM1 silencing led to a specific reduction of Pol II signal at 
the promoters and within the coding regions. This reduction, however, could not account 
for the inhibition of the transcriptional activity mediated by the PIM1 silencing. By 
contrast, the reduction of the elongating Pol II (Pol II-Ser2P) along the gene more closely 
correlated with transcript levels of both FOSL1 and ID2 suggesting that PIM1 silencing 
mostly affects the presence of Pol II engaged in transcript elongation.  
PIM1 contributes to the regulation of a subgroup of MYC-regulated genes. 
To understand the extent of PIM1 and MYC co-operation in gene transcription we 
performed expression profile analysis of 293 cells silenced either for MYC or PIM1 at 120 
minutes after serum treatment. MYC silencing affected the expression of 1026 genes of 
which 818 were up-regulated and 208 were down-regulated (see Supplementary 
Information Table SI) in line with previous analysis of MYC-regulated genes33. 
Comparison of genes regulated by MYC with those regulated by PIM1 showed that PIM1 
contributes to the regulation of 207 genes out of the 1026 MYC-regulated genes. Thus, 
20% of MYC-regulated genes, are also regulated by PIM1. Functional characterization of 
these genes, based on Gene Onthology categorization through the Panther database (http://
www.pantherdb.org), revealed that nucleic acid metabolism, transcriptional regulation, 
RNA processing, and oncogenesis are statistically overrepresented (P<0.05) (see 
Supplementary Information Table SII, SIII). Based on this analysis we conclude that PIM1 
act as a cofactor for transcriptional regulation in a significant subset of MYC-dependent 
genes. 
PIM1 recruitment to the chromatin by MYC contributes to cell transformation.
Next we investigated the biological relevance of MYC - PIM1 co-operation. First we 
verified whether PIM1 contributes to MYC-dependent regulation of cell cycle progression 
by silencing PIM1 in P493-6 cells, a cell line that depends on MYC expression for its 
proliferation27,34,35. Incorporation of [3H] thymidine was significantly decreased in 
PIM1 silenced cells and analysis of the cell cycle by FACS showed that PIM1 depletion 
determines a delay in S phase progression of these cells (see Supplementary Information 
Fig. S5).  
To test whether PIM1 cooperation with MYC in cell transformation and tumour growth is 
due to PIM1’s role in transcriptional activation of MYC-target genes, we performed 
transformation experiments in Rat-1 fibroblasts. Over-expression of MYC transforms these 
cells morphologically and induces them to grow in soft agar36. PIM1 silencing strongly 
inhibited the formation of soft agar foci, induced by MYC over-expression, and MYC 
silencing affected the number of foci induced by PIM1 over-expression to a similar extent, 
(Fig. 8a) thus, demonstrating that PIM1 is indeed required for MYC-dependent cell 
transformation. Moreover, the over-expression of MYC and PIM1 generates a significantly 
higher number of soft agar colonies than cells over-expressing either MYC or PIM1 (Fig. 
8a, b). 
To understand whether PIM1 acts as a MYC cofactor in cell transformation we generated 
chimeric constructs in which PIM1 was directly fused to the N terminal domain of MYC 
(PIM1-MYC). We found that the PIM1-MYC fusion molecule induced a comparable 
number of soft agar colonies relative to the co-expression of MYC and PIM1 in the same 
cells (Fig. 8b) suggesting that PIM1 recruitment to the chromatin by MYC is required for 
cooperation between MYC and PIM1 in cell transformation. Since formation of the MYC 
complex with PIM1 and its recruitment to MYC binding sites requires the MYC MBII 
domain (Fig. 2, 6), which is essential for MYC oncogenic activity, PIM1 was also fused to 
the transformation-defective MYC deleted in the MBII domain. Interestingly, we found that 
the fusion PIM1-MYC MBII, but not co-transfection of MYC MBII with PIM1, was 
able to rescue, at least in part, the defective MYC-transformation (Fig. 8b). Importantly, 
this fusion rescues both transcriptional activity and ability to phosphorylate H3S10 at its 
recruiting sites (Fig. 8d, f). In contrast, a chimeric molecule in which PIM1 was fused to a 
MYC C, a mutant unable to bind to the DNA, was defective for transforming activity and 
for phosphorylation of H3S10 at the target genes analysed (see Supplementary Information 
Figure S6). Interestingly, the transformed foci induced by the PIM1-MYC fusion grew 
vigorously in soft agar forming bigger colonies as compared with PIM1KD-MYC (see 
Supplementary Information Fig. S6).
Finally, we tested whether H3 phosphorylation at S10 is required for MYC-dependent 
transformation by analysing MYC transforming potential in the presence of either yellow 
fluorescent protein (YFP) fused to H3 (YFP-H3) or to H3 mutated in S10 (YFP-H3S10A). 
Both fusion proteins co-localised in the nucleus during interphase and mitosis together with 
the endogenous H3S10ph (see Supplementary Information Fig. S7) and they did not 
interfere with cell cycle progression (see Supplementary Information Fig. S7) as previously 
reported for other histone fusion proteins37. Then we performed transformation assays by 
either expressing MYC, PIM1 or PIM1-MYC fusion proteins in these cells (see 
Supplementary Information Fig. S8). We observed that, while YFP-H3 did not affect the 
number of foci, YFP-H3S10A mutant significantly reduced the number of soft agar 
colonies, FOSL1 and ID2 transcription as well as H3 phosphorylation at their MYC 
binding sites (see Supplementary Information Fig. S8). 
Taken together these results show that H3 phosphorylation at MYC-target genes by PIM1 
is required for the cooperative effects of PIM1 and MYC in cell transformation.  
DISCUSSION 
This study defines a new role for the serine/threonine kinase PIM1 as a MYC-dependent 
modifier of the chromatin. Based on biochemical and functional evidence, we show that 
following growth factor stimulation a MYC/MAX/PIM1 complex, formed in the nucleus, 
recruits PIM1 to the chromatin where it phosphorylates H3 at S10. This PIM1-dependent 
nucleosome phosphorylation is required for the transcriptional activation of a subset of 
MYC-target genes and MYC-dependent cell transformation. 
Immunoprecipitation experiments showed that following growth factor stimulation MYC, 
in conjunction with MAX, forms a complex with PIM1 in the nucleus. Silencing 
experiments demonstrated that MYC is required for PIM1 recruitment to the chromatin 
while PIM1 is necessary to phosphorylate the H3 at S10 on the nuclesosme at E boxes to 
activate the transcription.  According to the current view phosphorylation at the N-terminal 
domain of H3 could either be required to loosen the interaction between DNA and 
nucleosome and/or to generate a platform to recruit additional regulatory factors as 
described in the “histone code” hypothesis1. PIM1-dependent phosphorylation at the 
FOSL1 and ID2 genes is specific for its recruitment sites and does not spread over the 
genes, suggesting that this phosphorylation is necessary to trigger the enhancer to its active 
state. 
It was previously shown that upon growth factors treatment H3 is phosphorylated at S10 
with fast kinetics by MSK1/MSK24-7. Interestingly, FOSL1 shows two regions with 
different phosphorylation kinetics of H3S10: a phosphorylation site at the upstream SRE 
element, occurring within 15-30 minutes due to MSK1/MSK2, and a phosphorylation at the 
enhancer that was coincident with the peak of transcriptional activation of the gene 
mediated by PIM1. These two regions behaved differently with respect to acetylation of H3 
at K9 and K14. While at the FOSL1 promoter H3 phosphorylation and acetylation are 
tightly coupled as previously shown for other IE promoters3,38-40, at the FOSL1 enhancer, 
phosphorylation of H3S10 takes place in a region highly acetylated at H3 prior to MYC 
and PIM1 binding in agreement with the finding that for MYC recognition its target sites 
must be highly acetylated in H3 as well as methylated in H3K4/K7941. On the FOSL1 
enhancer phosphorylation and acetylation of H3 might have distinct functional roles as 
PIM1-dependent H3S10 phosphorylation is transient and limited to the E box element 
while acetylation at K9 and K14 is more stable and distributed along the gene suggesting 
that phosphorylation at these elements represents a critical step for the transcriptional 
activation. The fast turnover of H3 phosphorylation observed in our experiments and its 
temporal coincidence with transcriptional activation might be a general phenomenon as H3 
phosphorylation was previously detected with the transcriptional activation of heat shock 
genes in Drosophila and with the RAR 2 gene induction by retinoic agonists in murine 
P19 embryonal cells while acetylation was constitutive at these loci42,43. 
It has been estimated that about 11% of cellular genes present a functional E box to which 
MYC can associate on the genome28. MYC silencing demonstrated that MYC recruits 
PIM1 at specific MYC binding sites and confocal microscopy showed an elevated degree 
of nuclear co-localization of PIM1 with nascent transcripts and with MYC following 
growth factor treatment, suggesting that, at this stage of the cell cycle, PIM1 is recruited by 
MYC to a large number of sites. Gene expression profile analysis of MYC and PIM1 
regulated genes in cells treated with serum at 120 minutes, revealed that 207 transcripts, 
corresponding to 20% of MYC regulated genes, also require PIM1 for their regulation. The 
co-regulation includes genes involved in cell metabolism, protein synthesis, cycle 
progression, and oncogenesis. Interestingly, a large number of genes are transcriptional 
factors, which suggests that PIM1 participates in MYC-dependent regulatory networks. In 
agreement with these data cell cycle analysis, in PIM1 knockdown cells, revealed reduced 
entry in the S phase. Transformation analysis showed a  more dramatic PIM1 effect as 
PIM1 silencing strongly inhibited the formation of MYC-dependent transformed soft agar 
colonies. Although our experiments do not exclude that specific PIM1-regulated genes co-
operate with MYC in cell transformation, our data strongly suggest that PIM1-dependent 
phosphorylation of H3 at MYC-target genes is necessary to regulate key genes required for 
MYC-dependent oncogenic transformation. In fact, PIM1 fusion to the transformation 
defective MYC MBII could significantly rescue its transforming potential as well as H3 
phosphorylation at MYC binding sites while PIM1 co-expression with MYC MBII did 
not rescue. 
In conclusion, this study provides a molecular mechanism for MYC and PIM1 cooperation 
in gene regulation and oncogenic transformation. As mutations that alter MYC expression 
are among the most common found in human and animal cancers44, it is conceivable that 
inhibiting MYC association with PIM1 and/or inhibiting PIM1 kinase activity by specific 
drugs might represent a method for the treatment of cancers in humans. 
METHODS 
DNA constructs. Human PIM1 and MYC cDNA were cloned into pcDNA5/FRT 
(Invitrogen) vector under the control of the CMV/TetO2 tetracycline inducible promoter. 
The PIM1-K67M construct was generated by introducing a site-specific mutation in the 
DNA sequence corresponding to the lysine 67 to mutate it into a methionine (K67M). The 
MYC MBII construct was obtained by deleting the DNA sequence corresponding to the 
amino acids 119-152. The MYC C construct was obtained by deleting the DNA sequence 
corresponding to the amino acids 353-439. The PIM1-MYC fusion constructs were 
obtained by fusing the cDNA corresponding to PIM1 or PIM1-K67M via a 10 glycine 
encoding linker sequence to the cDNA corresponding either to MYC, MYC MBII or 
MYC C. 
shRNA constructs were obtained by cloning a double-stranded DNA cassettes into the 
pENTR/H1/TO vector, which allows the expression of shRNA under the control of the 
tetracycline inducible H1 promoter/TetO2. 
To generate shRNA cassettes the following oligonucleotides were designed following the 
manufacturer’s protocol. The 21-nucleotides positive strands are: 
PIM1 shRNA#1 (shPIM1#1):  5’-GTCTCTTCAGAGTGTCAGCAC-3’
PIM1 shRNA scrambled control#1 (shsP#1): 5’-GACTCATCAGTATGTTAGCAT-3’ 
PIM1 shRNA#2 (shPIM1#2): 5’-GAGGAAGAGAGTATCTATGGG
PIM1 shRNA scramble control#2 (shsP#2): 5’-GAAGCCGAGAGTATCTATGTT -3’
PIM1 shRNA#3 (shPIM1#3):  5’-CGAAGAAATCCAGGACCATCC -3’
PIM1 shRNA scrambled control#3 (shsP#3): 5’-AAGTCATCCGAAGACCACAAC-3’
PIM1 shRNA#4 (shPIM1#4):  5’-ACGTGGAGAAGGACCGGATTT-3’
PIM1 shRNA scrambled control #4 (shsP#4): 5’-GATTCGAGGACATGGACTGAG-3’
c-MYC shRNA#1 (shMYC#1):  5’-GCAATCACCTATGAACTTGTT-3’ 
c-MYC shRNA scramble control#1(shsM#1): 5’-GCATTCACCTAAGAAGTTCTT-3’  
c-MYC shRNA#2 (shMYC#2): 5’- GACGACGAGACCTTCATCAAA -3’
c-MYC shRNA2 scramble control #2 (shMYC#2): 5’-AGATCCAACCAGTCAGGACAT– 
3’
c-MYC shRNA#3 (shMYC#3):  5’-CCTGAGACAGATCAGCAACAA-3’ 
c-MYC shRNA scramble control#3 (shsM#3): 5’-CAACATGGTAACGAACAGCAA -3’
c-MYC shRNA#4 (shMYC#4):  5’-CAGTTGAAACACAAACTTGAA-3’ 
c-MYC shRNA scramble control#4(shsM#4): 5’-AACTAAGGTAACTATGCACAA-3’
c-MYC shRNA#5 (shMYC#5):  5’-CCATAATGTAAACTGCCTCAA-3’ 
c-MYC shRNA scramble control #5(shsM#5): 5’-GCAATGACCACCTATTCAATA-3’
The recombinant GST-PIM1 construct was obtained by cloning the PIM1 WT and PIM1-
K67M cDNA into the bacterial expression vector pGEX-4T and the fused protein was 
expressed and purified using the standard protocol.
The vector coding for Xenopus leavis histones were expressed and purified as previously 
described 45. Mutant recombinant histones H3 (H3S10A, H3S28A, H3S10A/S28A) were 
obtained by site directed mutagenesis as previously described 46.  YFP-H3 was kindly 
provided by Marco Bianchi and mutagenized as previously described 46. 
Cell culture condition. We generated tetracycline inducible 293 cell line stably expressing 
PIM1 WT or PIM1-K67M by using the Invitrogen’s Flp-T-Rex System.
pCDNA5/FRT/TO expression vector containing the gene of interest was inserted into the 
cells via Flp recombinase-mediated DNA recombination at the FRT site. The transfected 
cells were selected on the basis of hygromycin B (Sigma) resistance and pool clones were 
isolated.
Selected clones were cultivated in Dulbecco modified essential medium (D-MEM) 
containing 10% fetal bovine serum (FBS; Sigma) and 150µg/ml hygromycin for 2/3 weeks.
To perform time course experiments 293 cells were synchronized and then treated with 
50% serum shock as described 47. Primary HUVEC cells were grown in M199 medium 
supplemented with 15% fetal bovine serum, brain protein extracts and heparin (50 g/ml). 
The cells were then starved for 24 hours in M199 medium containing 1% FBS and 0.5% 
BSA and induced with 50 ng/ml of VEGF-A.
The cell line P493-6 (kindly provided by Bruno Amati) were grown in RPMI 1640 
containing 10% fetal calf serum (FCS) 100 U/ml penicillin, 100µg/ml streptomycin 2mM 
L-glutammine. MYC repression was obtained with 0.1 µg/ml tetracycline. MYC induction 
was obtained by washing the cells three times with tetracycline fee phophate buffered 
saline containing 10% FCS as previously described27.   
Immunostaining and co-localization analysis. Co-localization experiments were 
performed on fixed cells as previously described11 using a Leica TCS SP2 confocal 
microscopy. To label nascent RNA, anti-BrUTP (Sigma cat. B2531) has been utilized in 
permeabilized cells by immunodetection with small modifications from previously 
described protocol48. The degree of double staining was measured by quantitative analysis 
of the overlapping pixel using the Image J 1.32j (NIH, USA) software. All pixels having 
the same position in both images are considered coincident and the brightness level of each 
pixel is plotted as x and y axis of the scatter diagram. Two completely overlapping images 
will result in a straight diagonal line in scatter diagram.
Protein immunoprecipitation, interaction, kinase assays, chromatin 
immunoprecipitation. Proteins were extracted using F-buffer (10mM TRIS pH7.0, 
50mMNaCl, 30mM Na2HPO4, 50mM NaF, 5µM ZnCl2, 1% Triton-X 100) and treated 
with 1U/ml Micrococcal nuclease (Sigma) at 40C for 1hr to obtain the chromatin proteins 
(Chromatin fraction). 
To identify interacting protein, 0.5 mg of total proteins was incubated with 3 g of specific 
antibody overnight at 4° C. Immunocomplexes were incubated with Protein A- or G-
conjugated magnetic beads (DYNAL) for 30 minutes at 4°C. Samples were washed four 
times with F buffer and 2 times with 0,15M NaCl F-buffer for 20 minutes at 4°C. Proteins 
were eluded by boiling the samples and analysed by western blotting.
GST-interaction assay was performed by incubating 1mg of protein extracts (derived from 
chromatin fractions) with recombinant proteins GST, GST-PIM1WT and GST-PIM1-K67M 
bound to Glutathione-sepharose resin (Amersham). To allow specific interactions, proteins 
were incubated in Interaction buffer (TRIS 20mM; KCl 200mM; DTT 10mM; EGTA 
0,1mM; Glycerol 20%; Inhibitor protease cocktail) for 2 hours at 4°C in presence of 21-aa 
peptides. Unbound proteins were eliminated by 3 washes in the same buffer followed by 
protein equilibration in the Kinase buffer (TRIS 30mM; DTT 10mM; EGTA 0,1mM MnCl 
2mM; Glycerol 10%). Kinase assay was performed by incubating samples in the same 
buffer in presence of 4 pmol of [ -32P] ATP for 2 minutes at 30°C. Reaction was stopped 
by adding 10mM EDTA and samples were washed 6 times with Kinase buffer containing 
10mM EDTA and 200mM KCl. Phosphorylated proteins were separeted by SDS-PAGE 
and visualized by autoradiography.
Nucleosome core particles (NCPs) reconstitution was carry out as described 49. 
Chromatin Immunoprecipitation (ChIP) assays were performed as described by Upstate 
protocols (www.upstate.com). DNA was analyzed by quantitative real-time PCR by using 
Light Cycler DNA Amplification Kit SYBR Green I (Roche, Mannheim, Germany). All 
experiment values were normalized to those obtained with a non-immune serum and 
divided by input, using the procedure previously described 50. Experiments of MSK1/
MSK2 inhibition were performed by incubating cells with H89 (Calbiochem) as previously 
described 5. Oligonucleotide sequences will be provided upon request. 
Quantitative RT-PCR analysis was performed as previously described11. 
Cell transformation and colony formation in soft agarose
The analysis of cell transformation and anchorage independent growth were performed as 
previously described 36. Cells transfected with the constructs indicated were  
suspended at approximately 1x104 cells in 2 ml of 0.35% low-melting agarose onto  35-
mm culture dish containing 0.7% agarose base. Triplicates were prepared for each tested 
construct and inspected by eye after crystal violet staining for colony formation after 
incubation at 370C for 10-14 days. Efficiency of transfection was measured by reporter 
GFP gene and the levels of proteins were compared by Western blotting. 
 
Antibodies
The antibodies used for in this work are purchased by Santa Cruz Biotechnology (anti-
PIM1 SC-7856 for ChIP and immunofluorescence experiments; anti-PIM1 SC-13513 for 
Western blot analysis; anti-Myc SC-764 for ChIP and immunofluorescence experiments 
and anti-Myc SC-40 for Western blot analysis; anti-MAX SC-197 and SC-765; anti-SP1 
SC-59; anti-Pol II SC-899), by Covance anti Pol II Ser2 H5, by Upstate (anti-Histone H3 
06-755; anti-acetyl Histone H3 06-599; anti-phospho (Ser10)-acetyl (Lys14)-Histone H3 
07-081; anti-phospho (Ser10)- Histone H3 05-817), and by Abcam anti phospho (Ser10)-
acetyl (Lys9)-Histone H3 Ab 12181-50.
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FIGURE LEGENDS
Figure 1. PIM1 phosphorylates H3S10 on the nucleosome. 
(a) PIM1 phosphorylates histone H3 on nucleosomes from chromatin fraction. 
GST-recombinant proteins, as indicated, were incubated with purified nucleosomes 
from 293 cells and the kinase reactions were carried out in the presence of 
[  32P] ATP. GST-PIM1 interactions with nucleosomes were performed in the 
absence (-) or presence of 20 fold molar excess of unrelated (unr), H3 or H2B 
peptides as indicated. GST recombinant proteins and nucleosomes were 
visualized by Coomassie staining. Histone phosphorylation was revealed by 
autoradiography. H3 but not H2B N-terminal domain competes for PIM1 
association to the nucleosome inhibiting the kinase reaction. (Full scans are shown 
in Supplementary Information Figure S9).  
(b) PIM1 phosphorylates histone H3 at serine 10. Recombinant GST-PIM1 or the 
PIM1 kinase inactive mutant were incubated with nucleosomes reconstituted in 
vitro from recombinant histones. Nucleosomes were assembled containing 
respectively the histone H3 wild type (lanes 1, 2), the mutant H3S10A (lanes 3,4), 
the mutant H3S28A (lanes 5,6) or the double mutant H3S10A/S28A (lanes 7,8). 
Histone H3 autoradiography resulting from [ -32P] ATP incorporation (first panel) 
is shown. The input kinases and nuclesomes were visualized by Coomassies 
staining (lower panels).  
(c) PIM1 interacts with histone H3 in vivo. PIM1 was immunoprecipitated from 293 
stable clones expressing the inducible PIM1 (WT) or the kinase inactive mutant 
PIM1-K67M (K67M) as indicated. PIM1 and H3 were revealed by immunoblotting 
(IB) with specific antibodies. A kinase reaction (KA) was carried out incubating the 
PIM1/H3 co-immunoprecipitate in the presence of [  #32P] ATP. Histone 
phosphorylation was visualized by autoradiography. 2% of the total 
immunoprecipitated protein samples were loaded as inputs (lower panel). (Full 
scans are shown in Supplementary Information Figure S9).
 
Figure 2.  PIM1 forms a complex with MYC. 
(a) PIM1 co-localizes with MYC in HUVEC upon VEGF-A treatment. Indirect 
immunofluorescence analysis of HUVEC treated with VEGF was performed by 
using antibodies against PIM1 (red) and MYC (green) and double immunostaining 
are shown (Scale bar = 70µm). 
(b) VEGF-A treatment induced interaction of endogenous PIM1 with the MYC/MAX 
dimer. Cell proteins extracted from VEGF-A treated HUVEC were either 
immunostained (INPUT) or subjected to immunoprecipitation (IP) with anti-IgG 
antibodies (-), or anti-MAX antibodies as indicated (+). Immunostaining (IB) 
analysis was performed by using anti-MAX, -MYC and -PIM1 antibodies as 
indicated. 10% of the total immunoprecipitated protein samples were loaded as 
inputs. (Full scans are shown in Supplementary Information Figure S9).
(c) Endogenous PIM1 forms a complex with MYC/MAX in serum-stimulated 293. 
Western Blot analysis of input extracts, IgG, MAX, MYC or PIM1 
immunoprecipitates from serum induced or not induced as indicated. Interacting 
proteins were revealed by using anti-MAX, -MYC, or  -PIM1 antibodies 
respectively.
(d) MYC forms a complex with PIM1 through its MBII domain. 293 were transiently 
co-transfected with FLAG-MYC constructs as indicated and PIM1. Cell lysates 
were immunoprecipitated with anti-IgG, anti-FLAG, or anti-PIM1 antibodies 
followed by Western blot analysis to detect MAX, MYC, PIM1 and TRRAP proteins 
as indicated. Asterisk indicated an unspecific band. 
Figure 3. PIM1 co-localizes with H3S10ph, active chromatin, and MYC. 
(a) Immunofluorescence analysis of PIM1 nuclear sub-localization in HUVEC 
treated with VEGF for 60 minutes. Fixed cells were double-stained for PIM1 (red) 
and one of the indicated markers (green) (Scale bar = 8µm). The corresponding 
pictures were merged and all pixels having the same position in both images are 
considered coincident and were represented as white spots (co-localization 
points). The brightness level of each pixel is plotted as x (PIM1) and y (marker) 
axis of the scatter diagram of the correlation plot. The pixels co-localization results 
of 7 individual images represented in the correlation plot were quantified as 
Pearson’s correlation coefficient (Rr) as mean ± SD with P values determined 
using Student's t-test. 
(b) Immunofluorescence analysis of MYC localization at transcriptional active sites. 
Cells were labeled with BrUTP and detected with anti-bromodeoxyuridine antibody 
(green). Double labeling was revealed at transcriptional active sites by staining 
cells with an anti-MYC antibody (red). The pixels co-localization were performed as 
in (a). 
Figure 4. PIM1 associates to chromatin at the FOSL1 enhancer. 
(a) FOSL1 is transiently induced by VEGF-A treatment. Serum-starved HUVEC 
were treated with VEGF-A and total RNAs were collected at different time points. 
FOSL1 transcript levels were quantified by quantitative RT-PCR and relative 
values normalized on GAPDH expression level. The values represent the mean s. 
d. of three replicate samples from one representative experiment (n = 3). (b) 
Schematic representation of the FOSL1 gene region including the first two exons 
(not in scale). Exons are represented as black squares within the gene and the E 
box is figured as a black spot. The probes used in ChIP analysis are indicated. 
PCR probes intervals are numbered relatively to the fist nucleotide of exon 1 (+1).
(c) VEGF-A induces PIM1 association with chromatin at the FOSL1 enhancer. 
Protein interactions on FOSL1 chromatin were measured by quantitative ChIP 
assay on VEGF-A-treated HUVEC. Chromatin extracts were immunoprecipitated 
using antibodies as indicated. Real-time quantitative PCR measurements of the 
immunoprecipitated DNA of the corresponding gene regions identified as probes A, 
B, C or D at different time points are expressed as 1/1000 (‰) of the DNA inputs. 
The values represent the mean s. d. of three replicate samples from one 
representative experiment (n = 3).
(d) FOSL1 expression in the presence of MSK1/MSK2 inhibitor H89. Serum-
starved HUVEC were treated with VEGF-A in the presence or absence of 10 µM 
H89 and total RNAs were collected at different time points. FOSL1 transcript levels 
were quantified by real-time quantitative RT-PCR and relative values normalized 
on GAPDH expression level. The values represent the mean s. d. of three replicate 
samples from one representative experiment (n = 3).
(e) Phosphorylation of H3S10 at the FOSL1 upstream element is dependent from 
MSK1/MSK2 kinase activities. H3S10 phosphorylation was measured by 
quantitative ChIP assay on VEGF-A-treated HUVEC. Chromatin extracts were 
immunoprecipitated using antibodies as indicated. Real-time quantitative PCR 
measurements of the immunoprecipitated DNA of the corresponding gene regions 
identified as probes A, B, C or D at different time points are expressed as 1/1000 
(‰) of the DNA inputs. The values represent the mean s. d. of three replicate 
samples from one representative experiment (n = 3).
Figure 5.  PIM1 mediates H3S10 phosphorylation and contributes to FOSL1 
transcription.
(a) Inducible shRNA expression targeting PIM1. Western blot analysis of 293 
stable clones expressing a control scrambled shRNA (shsP#1) or PIM1 shRNA 
(shPIM1#1) inducible by tetracycline. Immunostaining with antibodies as indicated. 
Protein extracts were obtained from not treated or serum-treated cells as indicated, 
in presence (Tet +) or absence (Tet -).
(b) PIM1 knockdown alters H3S10 phosphorylation at the FOSL1 enhancer. 
Probes A, B, C and D are schematized as in Figure 4. Time course analysis by 
ChIP assay was performed by using antibodies as specified from 293 cells 
expressing either a control scrambled shRNA or PIM1 shRNA. Real-time 
quantitative PCR measurements of the immunoprecipitated DNA are expressed as 
1/1000 (‰) of the DNA inputs. The values represent the mean s. d. of three 
replicate samples from one representative experiment (n = 3).
Figure 6. PIM1 phosphorylates histone H3 in a MYC-dependent manner. 
(a) Inducible MYC gene silencing. 293 were transiently transfected with either a 
control scrambled shRNA (shsM#1) or MYC shRNA (shMYC#1) as indicated by 
tetracycline treatment. Western blot analysis on protein extracts was performed by 
immunoblotting, using antibodies recognising MYC, MAX, or SP1 as indicated. 
(b-e) MYC recruits PIM1 on chromatin. Chromatin samples were obtained from 
serum-induced 293 cells expressing the control scrambled shRNA  or MYC shRNA 
as indicated.  ChIP assays were performed using antibodies as indicated. 
Immunoprecipitated DNA was analyzed by quantitative PCR with primers to 
amplify the FOSL1 enhancer and ID2 upstream MYC-bindig sites (-1705/-1460). 
Real-time quantitative PCR measurements of the immunoprecipitated DNA are 
expressed as 1/1000 (‰) of the DNA inputs. The values represent the mean s. d. 
of three replicate samples from one representative experiment (n = 3).
(f) Western blot analysis of 293 transiently transfected with control scrambled 
shRNA (shsM#1), MYC shRNA (shMYC#1), or the shRNA together with plasmids 
expressing either FLAG-MYC or FLAG-MYC MBII as indicated. shMYC#1 
recognizes MYC 3’-untranslated region which is not present in the FLAG 
constructs co-transfected. Protein expression was performed by immunoblotting, 
using antibodies as indicated. 
(g-h) MYC but not FLAG-MYC BMII rescues the recruitment of PIM1 to the 
chromatin. Chromatin samples were obtained from 293 cells expressing the control 
scrambled shRNA, MYC shRNA, or the shRNA together with FLAG-MYC or FLAG-
MYC MBII (F-MYC MBII) as indicated. ChIP assays were performed using 
antibodies as indicated. Immunoprecipitated DNA was analyzed by quantitative 
PCR with primers to amplify the FOSL1 enhancer and ID2 upstream MYC-binding 
sites (-1705/-1460). Real-time quantitative PCR measurements of the 
immunoprecipitated DNA and expressed as 1/1000 (‰) of the DNA inputs. The 
values represent the mean s. d. of three replicate samples from one representative 
experiment (n = 3).
Figure 7. PIM1 is required for the transcriptional activation of FOSL1 and ID2. 
(a, d) Schematic representation of the FOSL1 and ID2 gene regions (not in scale). 
Exons are represented as black squares E boxes are figured as a black spot. The 
probes used for ChIP analysis are indicated. PCR probes are numbered relatively 
to the fist nucleotide of exon 1 (+1). 
(b) Time-course analysis by quantitative real time RT-PCR of FOSL1 mRNA and 
unprocessed heterogeneous nuclear FOSL1 RNA (hnRNA) in 293 cells expressing 
either a control scrambled shRNA or PIM1 shRNA as indicated. Gene specific RNA 
levels were measured and normalized on GAPDH expression and represented as 
fold induction (vertical bars). Real-time quantitative RT-PCR measurements. The 
values represent the mean s. d. of three replicate samples from one representative 
experiment (n = 3).
(c) Time course analysis by ChIP assay was performed by using antibodies 
recognising RNA Polimerase II (Pol II) or RNA Polimerase  II phosphorylated in its 
C terminal domain at Serine 2 (Ser2P) from 293 cells expressing either a control 
scrambled shRNA or PIM1 shRNA at the FOSL1 promoter or coding region as 
specified in panel A. Real-time quantitative PCR measurements of the 
immunoprecipitated DNA and expressed as 1/1000 (‰) of the DNA inputs. The 
values represent the mean s. d. of three replicate samples from one representative 
experiment (n = 3).
(e) Time-course analysis by quantitative real time RT-PCR of ID2 mRNA and ID2 
hnRNA in 293 cells expressing either a control scrambled shRNA (shsP#1) or 
PIM1 shRNA (shPIM1#1). RNA levels were measured and normalized on GAPDH 
expression and represented as fold induction (vertical bars) by Real-time 
quantitative RT-PCR measurements. The values represent the mean s. d. of three 
replicate samples from one representative experiment (n = 3).
(f) Time course analysis by ChIP assay was performed by using antibodies 
recognising RNA Polimerase II (Pol II) or RNA Polimerase II phosphorylated in its 
C terminal domain at Serine 2 (Ser2P) from 293 cells expressing either a control 
scrambled shRNA or PIM1 shRNA at the ID2 promoter or coding region as 
specified in panel D. 
Real-time quantitative PCR measurements of the immunoprecipitated DNA are 
expressed as 1/1000 (‰) of the DNA inputs. The values represent the mean s. d. 
of three replicate samples from one representative experiment (n = 3).
 
Figure 8. PIM1 contributes to MYC-dependent transformation. (a b) Soft agar 
colony formation of Rat-1 cell lines. Rat-1 fibroblasts were transfected with the 
constructs indicated. Transforming potential of the transfected constructs was 
determined by examining the soft agar colonies formed within two weeks post-
transfection. Transforming potential was estimated by the average number of 
visible soft agar colonies observed in three plates. A representative experiment is 
shown. 
(c-d) Quantitative real time RT-PCR of FOSL1 and ID2 mRNA in Rat-1 cells 
expressing the constructs indicated. Gene specific RNA levels were measured and 
normalized on GAPDH expression and represented as fold induction (vertical bars) 
by real-time quantitative RT-PCR measurements. The values represent the mean 
s. d. of three replicate samples from one representative experiment (n = 3).
(e-f) ChIP assay performed in Rat-1 cells by using antibodies as indicated. The 
primers used for the FOSL1 gene correspond to probe B shown in Figure 4 and for 
the ID2 MYC binding sites as in Figure 7. Real-time quantitative PCR 
measurements of the immunoprecipitated DNA are expressed as 1/1000 (‰) of the 
DNA inputs. The values represent the mean s. d. of three replicate samples from 
one representative experiment (n = 3).
